Biologic and targeted synthetic disease-modifying anti-rheumatic drugs improve body composition in rheumatoid arthritis patients more than conventional synthetic disease-modifying anti-rheumatic drugs: Results from the PRESENT study.
Humans
Arthritis, Rheumatoid
/ drug therapy
Male
Female
Body Composition
/ drug effects
Antirheumatic Agents
/ therapeutic use
Prospective Studies
Aged
Treatment Outcome
Middle Aged
Sarcopenia
/ physiopathology
Biological Products
/ therapeutic use
Time Factors
Janus Kinase Inhibitors
/ therapeutic use
Tumor Necrosis Factor Inhibitors
/ therapeutic use
Japan
Muscle, Skeletal
/ drug effects
b/tsDMARD
muscle mass
prospective observational study
rheumatoid arthritis
sarcopenia
Journal
International journal of rheumatic diseases
ISSN: 1756-185X
Titre abrégé: Int J Rheum Dis
Pays: England
ID NLM: 101474930
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
revised:
28
08
2024
received:
02
07
2024
accepted:
25
09
2024
medline:
9
10
2024
pubmed:
9
10
2024
entrez:
9
10
2024
Statut:
ppublish
Résumé
The effects of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) and conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) on body composition and muscle function in rheumatoid arthritis (RA) patients requiring treatment enhancement were compared. This multicenter, prospective, observational study (PRESENT Study) divided RA patients non-randomly into a csDMARD group (n = 100) and a b/tsDMARD group (n = 100). Changes in body composition and muscle function were examined in 80 patients in each group followed for 52 weeks. The percentages of new-onset and improved sarcopenia over 1 year were investigated. Patients in the b/tsDMARD group were divided into three groups by drug type: TNF inhibitors (n = 30), non-TNF inhibitors (n = 23), and JAK inhibitors (n = 27). Baseline median age and disease duration were 70.0 and 4.0 years, respectively. Changes in weight (24 and 52 weeks) and muscle mass (52 weeks) were significantly higher in the b/tsDMARD group (p = .035, p < .001, and p = .002, respectively). On multivariate logistic regression analysis, b/tsDMARD treatment (OR 3.21, p = .002), DAS28-ESR (OR 0.65 p = .011), and muscle mass (OR 0.90, p = .023) were independently associated with increased muscle mass at 52 weeks. The percentages of new-onset and improved sarcopenia were almost equal. There were no significant differences in the time-dependent changes (52 weeks) of clinical status, body composition, muscle function, and status of sarcopenia among TNF inhibitors, non-TNF inhibitors, and JAK inhibitors. Weight and muscle mass increased significantly more with b/tsDMARD than with csDMARD treatment. There were no differences in body composition changes by mode of action with b/tsDMARDs.
Identifiants
pubmed: 39381837
doi: 10.1111/1756-185X.15371
doi:
Substances chimiques
Antirheumatic Agents
0
Biological Products
0
Janus Kinase Inhibitors
0
Tumor Necrosis Factor Inhibitors
0
Types de publication
Journal Article
Observational Study
Multicenter Study
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15371Informations de copyright
© 2024 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
Références
Brance ML, Di Gregorio S, Pons‐Estel BA, et al. Prevalence of sarcopenia and whole‐body composition in rheumatoid arthritis. J Clin Rheumatol. 2021;27:S153‐S160.
Okano T, Inui K, Tada M, et al. Loss of lean body mass affects low bone mineral density in patients with rheumatoid arthritis ‐ results from the TOMORROW study. Mod Rheumatol. 2017;27:946‐952.
Cruz‐Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16‐31.
Chen LK, Woo J, Assantachai P, et al. Asian working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21(300–307):300‐307. e2.
Yoshimura N, Muraki S, Iidaka T, et al. Prevalence and co‐existence of locomotive syndrome, sarcopenia, and frailty: the third survey of research on osteoarthritis/osteoporosis against disability (ROAD) study. J Bone Miner Metab. 2019;37:1058‐1066.
Li TH, Chang YS, Liu CW, et al. The prevalence and risk factors of sarcopenia in rheumatoid arthritis patients: a systematic review and meta‐regression analysis. Semin Arthritis Rheum. 2021;51:236‐245.
Tada M, Yamada Y, Mandai K, Hidaka N. Matrix metalloprotease 3 is associated with sarcopenia in rheumatoid arthritis ‐ results from the CHIKARA study. Int J Rheum Dis. 2018;21:1962‐1969.
Bennett JL, Pratt AG, Dodds R, Sayer AA, Isaacs JD. Rheumatoid sarcopenia: loss of skeletal muscle strength and mass in rheumatoid arthritis. Nat Rev Rheumatol. 2023;19:239‐251.
Huo YR, Suriyaarachchi P, Gomez F, et al. Phenotype of osteosarcopenia in older individuals with a history of falling. J Am Med Dir Assoc. 2015;16:290‐295.
Tada M, Yamada Y, Mandai K, Matsumoto Y, Hidaka N. Osteosarcopenia synergistically increases the risk of falls in patients with rheumatoid arthritis. Osteoporos Sarcopenia. 2021;7:140‐145.
An HJ, Tizaoui K, Terrazzino S, et al. Sarcopenia in autoimmune and rheumatic diseases: a comprehensive review. Int J Mol Sci. 2020;21:5678.
Torii M, Itaya T, Minamino H, et al. Management of sarcopenia in patients with rheumatoid arthritis. Mod Rheumatol. 2023;33:435‐440.
Ben Tekaya A, Mehmli T, Ben Sassi M, et al. Effects of biologic and target synthetic disease‐modifying anti‐rheumatic drugs on sarcopenia in spondyloarthritis and rheumatoid arthritis: a systematic review and meta‐analysis. Clin Rheumatol. 2023;42:979‐997.
Hein TR, Peterson L, Bartikoski BJ, Portes J, Espírito Santo RC, Xavier RM. The effect of disease‐modifying anti‐rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta‐analysis. Arthritis Res Ther. 2022;24:171.
Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580‐1588.
Kawahito Y, Morinobu A, Kaneko Y, et al. Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis‐secondary publication. Mod Rheumatol. 2023;33:21‐35.
Haraoui B, Smolen JS, Aletaha D, et al. Treating rheumatoid arthritis to target: multinational recommendations assessment questionnaire. Ann Rheum Dis. 2011;70:1999‐2002.
Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‐modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3‐18.
Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty‐eight‐joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44‐48.
Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42:244‐257.
Pincus T, Summey JA, Soraci SA Jr, et al. Assessment of patient satisfaction in activities of daily living using a modified Stanford health assessment questionnaire. Arthritis Rheum. 1983;26:1346‐1353.
Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA. 1949;140:659‐662.
Tada M, Yamada Y, Mandai K, Hidaka N. Correlation between frailty and disease activity in patients with rheumatoid arthritis: data from the CHIKARA study. Geriatr Gerontol Int. 2019;19:1220‐1225.
Tada M, Yamada Y, Mandai K, Hidaka N. Relationships of the stand‐up time to falls and fractures in patients with rheumatoid arthritis: results from the CHIKARA study. Int J Rheum Dis. 2021;24:246‐253.
Yamada Y, Tada M, Mandai K, Hidaka N, Inui K, Nakamura H. Glucocorticoid use is an independent risk factor for developing sarcopenia in patients with rheumatoid arthritis: from the CHIKARA study. Clin Rheumatol. 2020;39:1757‐1764.
Tam K, Wong‐Pack M, Liu T, et al. Risk factors and clinical outcomes associated with sarcopenia in rheumatoid arthritis: a systematic review and meta‐analysis. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2024;30:18‐25.
Tournadre A, Pereira B, Dutheil F, et al. Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J Cachexia Sarcopenia Muscle. 2017;8:639‐646.
Toussirot E, Marotte H, Mulleman D, et al. Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12‐month multicentre study. Arthritis Res Ther. 2020;22:224.
Ferraz‐Amaro I, Arce‐Franco M, Muñiz J, et al. Systemic blockade of tnf‐α does not improve insulin resistance in humans. Horm Metab Res. 2011;43:801‐808.
Vial G, Lambert C, Pereira B, et al. The effect of TNF and non‐TNF‐targeted biologics on body composition in rheumatoid arthritis. J Clin Med. 2021;10:10.
Doles JD, Olwin BB. The impact of JAK‐STAT signaling on muscle regeneration. Nat Med. 2014;20:1094‐1095.
Nishina N, Kaneko Y, Kameda H, Kuwana M, Takeuchi T. Reduction of plasma IL‐6 but not TNF‐α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression. Clin Rheumatol. 2013;32:1661‐1666.